The reproductive safety of GLP-1 receptor agonists in metabolically healthy, normal-weight women is mainly unexplored, since existing human clinical data mostly concentrate on women with obesity or polycystic ovary syndrome. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.